CATEGORIES: Clinical Trials | Research

Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT) Calling CMT1A Patients Ages 18-75

by | Sep 1, 2020 | 2 comments

This study is a new international research project funded by the National Institutes of Health (NIH) called Accelerate Clinical Trials in Charcot-Marie-Tooth Disease (ACT-CMT). Dr. David Herrmann at the University of Rochester is the study’s Principal Investigator. There are 3 participating centers in the USA. 

※ University of Rochester, NY (Dr. David Herrmann, shown in photo below) 

※ University of Pennsylvania, PA (Dr. Steve Scherer) recruitment completed

※ University of Iowa, IA (Dr. Mike Shy) 

This study is enrolling people with CMT1A who are aged 18-75. 

The purpose of this study is to determine the best way to measure the progression of Charcot-Marie-Tooth Disease Type 1A (CMT1A) over time. This study is important to help us to prepare for clinical trials. We are looking at new ways of measuring changes in CMT1A progression over a short period of time and assessing their usefulness in measuring effects of treatments in future clinical trials.  In addition to measurements that are currently used to measure progression of CMT1A such as strength and sensation, this study would also include the following: 

※ Two questionnaires (the CMT Health Index and Overall Neuropathy Limitation Scale) that explore how you think CMT1A affects you

※ CMT Functional Outcome Measure (CMT-FOM) which assesses balance, walking, standing up from sitting in a chair, and manual dexterity 

※ We will also test your ability to feel nylon monofilaments (like fishing line) and photographing a small area of your hand using a non-invasive microscope that can look into the skin and see nerve endings 

※ Nerve conduction studies on one arm and one leg 

※ For some participants, an MRI scan of your lower leg muscles The study visits are approximately 4 hours (with an additional hour for optional MRI). 

The study visits are at 6-12 month intervals for up to 3 years. Participants will receive an honorarium and reimbursement of qualified travel expenses.  For more information about participating, please contact:   

University of Rochester 

Steffen Behrens-Spraggins (585) 275-5760 

Steffen_Behrens-spraggins@URMC.Rochester.edu   

University of Iowa 

Alexa Bacha (319) 467-5006 

[email protected]

Learn more on this topic

Related Blog Posts

Breaking News: First Therapeutic Gene Therapy to Treat an Inherited Neuropathy is Approved for Clinical Trial!

The first disease community to receive a therapeutic gene to the spinal cord for an ultra rare inherited neuropathy is Giant Axonal Neuropathy (GAN). Congratulations to Hannah’s Hope Fund (HHF), a 501(c)3 public charity, which has driven this collaborative research in less than six years. Six million dollars has been raised to date to fund pre-clinical and clinical research on this rare disease.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Join the conversation

Leave a Comment

2 Comments

  1. Dr. Roberta DeLuca

    My husband has CMT. I was totally unaware there was a community! We live in Central California and could be interested in some help or studies.

    Reply
  2. Roxanne

    HI there.
    Are there any clinical trials or research centres in South Africa.

    Reply

Leave a Reply to Roxanne Cancel reply

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news